WinstonWınston
Moderna logo

Moderna

MRNA
16
Biotechnology · Healthcare
Price
$61.82
-1.33 (-2.11%)
Market Cap
$24.53B
Exchange
NASDAQ
Winston Score
16
Winston is worried
Weak fundamentals across most pillars.

Share count falling — buybacks

9.7% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 431.0M (2021) → 389.0M (2025)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus

Winston Score History

Politician Trades

7 trades / 12mo

4 Congressional buys and 3 sells on MRNA in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+263.6% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

-34.9% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$3.1B/ year

Declining (-31% vs prior year)

161.1% of revenue

9.0x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

6.7%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~8 months

$1.9B cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Revenue accelerating

Moderna grew revenue 264% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
-145.5%
Thin — -145.5% gross margin
Operating Margin
-356.8%
Losing money on operations — -356.8%
ROCE
-17.2%
Weak — -17.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
-29.1%
Shrinking sales (-29.1% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
0/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
-71.1%
Burning cash (-71.1%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.09
Conservative — low debt load (0.09)
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial